**Summary:**
A notice issued on the 15th of some month in 20XX (date illegible in source text) by the Directorate General of Health Services, Office of Drugs Controller General India (DCGI), FDA Bhawan, New Delhi, addresses concerns related to the marketing of drugs represented as similar to stem cells for treating various diseases. The notice emphasizes that stem cell-derived products fall under the purview of the Drugs and Cosmetics Act, 1940, and related regulations, requiring them to meet specific safety and efficacy standards before they can be marketed. The DCGI is concerned about unsubstantiated claims and potential risks associated with unregulated stem cell therapies. The notice alerts all State Licensing Authorities and Zonal/Sub-zonal offices of CDSCO to ensure that stem cell-based products are not manufactured/marketed without due approval and compliance with existing regulations. The communication is addressed to all Pharmaceutical Associations and JDCs/DDCs/ADCs of CDSCO HQ. The notice is issued by Dr. GN. Singh, Drugs Controller General India.
Key Entities Referenced
Directorate General of Health Services: An organization, likely a part of the Indian government's health administration.
Drugs Controller General India: A key regulatory position within the Indian pharmaceutical sector, responsible for drug regulation and control.
FDA Bhawan, Kotla Road, New Delhi: Address of the Office of Drugs Controller General India, located in New Delhi, Delhi.
Pharmaceuticals Associations: Refers to organizations representing pharmaceutical companies and interests.
CDSCOHQ: Likely refers to the headquarters of the Central Drugs Standard Control Organisation.
Dr. GN. Singh: The Drugs Controller General of India, as identified in the document.
JDCs/DDC1s/ADC1s: These abbreviations likely refer to different levels of drug control officers within the CDSCO: Joint Drugs Controllers, Deputy Drugs Controllers, and Assistant Drugs Controllers.
New Delhi, Delhi: The city and state where the office of Drugs Controller General India is located.
F.No. 12-01/2014-DC
(Pt-20)
Directorate General of Health Services
Office of Drugs Controller General (India)
FDA Bhawan,
Kotla Road, New Delhi
Dated: 15 pg ~ 20\b
Notice
ac.W roFe ei nl x d af e lua d scr ote D e c M o d ate o s le le ia et nd di C v On toig / omc obe po i rf DD n e C saS C G etu G n(b i( tj o I1 e n t))c s h t e, t ii oE n r G x r clmp e aoae v st br i et at e e l bwr C e s Co f tl om r hi rem en eli i a act St ba ut e l o bde v je Tt ee ro c c i to aa a ln p p Ess p p x,t lr pi io et cv ru B aat ti tle o i Cd l oo oo nb f g msy i mN c b it ae y th l we
t
t ehM D & e ei r n eu M di xg ues ps rdt e, iir r nc ty S ga s u o l tb .f hs T eDH e h ee meq va
e
u i al ee pct tn peh it l
n
s ia
g
N cn .a aed r ne w t F a b fDm e ir rii u mnl sg gy
sSwpfm hiri Ee aer t le Cs lm ht s e di bm n rn a eec arg ee ae w t t o n ih if t ne n a h r g S ene su t d s b h b osj e ty lhe h a e c ea l mt dld e m iv eE a sbi tx ct es ip rt e ee n e cd tr g r o it t n ow h s ni iC a s i lto dl om emo fm b r a tni e enc h t dde ett a r ae t t De fhe o a Cte, tr ei Ge y rr (d T , a Dth ap hi )sp f es l a y ci i m llc ta oia ut snt rt g ei n e do ir n w n Is h gh n i a a c wcrs l re h u i b si te i tn te o ehcn e nnl i uv jr od u i fe sae d ttpw ihpi fe eln iid i crt c a hs a a te e t ipr oi pAi no lo g n iu fe s cs o anl rty d w i. i ta o l hnA l eo sl if l rb i t ne at h h be se s t u S er ba E e nsp aC cp et, el qe i d ut ac eha ne nan i dtst r
(Dr. GN. Singh)
Drugs Controller Geneyal (India)
Copt to
1. All Pharmaceuticals
Associations
2. All JDC()s/DDC(1)s/ADC(1)s/
of CDSCO(HQ)